MarketInOut Stock Screener Log In | Sign Up
 

Neurocrine Biosciences Inc

NASDAQ • Healthcare • Drug Manufacturers - Specialty & Generic • Quote as of 05/13/2026 10:35
Neurocrine Biosciences Inc stock price and volume chart

Company Profile

IndustryDrug Manufacturers - Specialty & Generic
SectorHealthcare
ExchangeNASDAQ
Market Capitalization15,198 mln
Float99.26 mln
Earnings Date08/04/2026

EPS

6.50
Strong

P / E

24.49
Premium valuation

Piotroski F-Score

6 / 9
Solid

Beneish M-Score

-2.45
Borderline

1-Year Forecast

191
Attractive

Relative Strength

92 / 100
Top performer

Business Description

Neurocrine Biosciences is a San Diego-based pharmaceutical company, founded in 1992, that researches and sells treatments for brain, hormonal, and immune-related conditions across the US and globally. Its marketed products address conditions such as tardive dyskinesia, Huntington's disease, endometriosis, uterine fibroids, and congenital adrenal hyperplasia. The company has a broad pipeline of experimental treatments targeting depression, schizophrenia, epilepsy, Alzheimer's disease, and obesity, among others. It also works alongside several major pharmaceutical partners, including AbbVie, Sanofi, and Takeda, through licensing and collaboration agreements.

Key Fundamentals

EPS6.50
P/E24.49
ROE22.45
RPS30.18
ROIC20.29
ROA15.64
EBITDA, mln829
EV / EBITDA17.98
EV / EBIT18.65
Revenue, mln3,102
EV / Revenue4.80

Financial Strength

Altman Z-Score7.48
Piotroski F-Score 6 / 9
Beneish M-Score-2.45
Price to Lynch Fair Value1.16
Price to Graham Number2.28
1-Year Target Price191
Shiller PE Ratio102
Short Ratio5.23
Short % of Float7.31

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week 8.13% 92 / 100   
1 Month 21.54% 89 / 100   
2 Months 15.32% 80 / 100   
6 Months 5.97% 60 / 100   
1 Year 32.01% 72 / 100   



Disclaimer - Privacy Policy - Terms Of Service - Cookie Use Policy - FAQ - Contact Us